Eterna Therapeutics Inc

$0.20
(as of Apr 24, 3:48 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Eterna Therapeutics Inc

Stock Price
$0.20
Ticker Symbol
ERNA
Exchange
NASDAQ

Industry Information for Eterna Therapeutics Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Eterna Therapeutics Inc

Website
https://www.ernexatx.com
Country
USA
Full Time Employees
6

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Fundamentals for Eterna Therapeutics Inc

Market Capitalization
$12,050,271
EBITDA
$-17,111,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-3.39
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
62,178,900
Percent Owned by Insiders
69.03%
Percent Owned by Institutions
1.60%
52-Week High
52-Week Low

Technical Indicators for Eterna Therapeutics Inc

50-Day Moving Average
200-Day Moving Average
RSI
44.18
ATR
0.02

Analyst Ratings for Eterna Therapeutics Inc

Strong Buy
Buy
Hold
Sell
Strong Sell

News About Eterna Therapeutics Inc

Apr 22, 2025, 8:30 AM EST
CAMBRIDGE, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that new data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. See more.
Apr 3, 2025, 8:55 AM EST
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it has entered into a securities purchase agreement with accredited investors for the private placement of approximately 69.3 million shares of common stock (or pre-funded warrants to purchase shares of common stock), at a purchase price of $0.1046 per share for an aggregate purchase price of approximately $7,250,000, assuming the Company receives stockholder approval. See more.
Feb 26, 2025, 8:30 AM EST
CAMBRIDGE, Mass., Feb. See more.
Nov 1, 2023, 8:30 AM EST
CAMBRIDGE, Mass., Nov. See more.